Chemical compound (psychedelic drug) AL-LAD, or ALLAD, also known as ALLY-LAD or as 6-allyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally. The drug interacts with serotonin and dopamine receptors and is known to act as an a

How long does AL-LAD last?

The total duration of AL-LAD via oral is 7 hours to 10 hours. Onset typically occurs within 20 minutes to 1 hour. Peak effects last 2.5 hours to 5 hours.

AL-LAD — SubstanceWiki

SubstanceWiki

⌘K

How It Feels

The first thing you notice is the light. Within twenty minutes of ingestion, light sources seem to become more generous, spilling their illumination further into the room, catching on surfaces that would normally be unremarkable. A glass of water on the table begins to throw tiny rainbows. The grain of the wooden floor starts to drift and swim. AL-LAD wastes no time establishing its visual credentials.

The body feels clean and energized. There is a notable absence of the heavy body load that can accompany other lysergamides. Instead, a pleasant electric warmth courses through the limbs, and the skin becomes exquisitely sensitive to touch and temperature. Movement feels fluid and rewarding. The stomach remains calm. For many, this physical transparency is AL-LAD's most appealing quality: it lets the experience unfold without the gravitational pull of somatic distress.

At peak intensity, the visual display reaches extraordinary heights. Every surface becomes a screen for fractal geometry, tessellating and morphing in real time. Colors achieve a saturated intensity that seems to exceed the normal gamut of human vision, impossible greens, ultraviolet blues, reds that pulse with their own inner light. Tracers follow moving objects with calligraphic grace. Yet beneath this visual extravaganza, the mind remains remarkably clear. The deep existential questioning and ego dissolution that characterize LSD are largely absent. Thoughts are lucid, conversation is easy, and there is a persistent undertone of playfulness and delight. You are watching the most magnificent light show of your life and you have the mental clarity to appreciate every detail.

The curtain falls relatively early. By five to six hours the intensity has clearly waned, and by eight hours most people feel essentially baseline. The brevity is a relief for some and a disappointment for others. The afterglow is clean and bright, a lingering enhancement of color perception and a quiet sense of well-being that can persist into the following day. There is minimal cognitive fog, minimal physical depletion, just a memory of extraordinary beauty and the clear-eyed awareness to have witnessed it.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(13)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(15)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...

Pharmacology

AL-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from AL-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

AL-LAD shares many common traits with its parent compound LSD; in humans it appears to be roughly equal (if slightly less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily). In rats, however, AL-LAD was measured to be around twice the potency of LSD, and this may extend to AL-LAD.

There are currently anecdotal reports which describe the effects of this compound within our experience index.

The toxicity and long-term health effects of recreational AL-toxic dose is unknown. This is because AL-LAD is a research chemical with very little history of human usage.

The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute AL-LAD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, AL-LAD is able to be considered non-addictive,extremely low toxicity relative to dose. It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute AL-LAD exposure.

However, as with LSD and psychedelics in general, it is possible that AL-LAD can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, AL-not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of AL-almost immediately after ingestion. After that,5-714 days to be back at baseline (in the absence of further consumption). AL-LAD presents cross-tolerance with Cross-all psychedelics, meaning that after the use of AL-LAD all psychedelics will have a reduced effect.

Overdose

The LD50 of AL-LAD is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of AL-LAD.

AL-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.

Austria: AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Denmark: As of August 25, 2015, AL-LAD is specifically named on the list of illegal substances.
Germany: AL-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: AL-LAD is a controlled substance in Japan effective February 28th, 2020.
Latvia: AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Sweden: Following its sale as a designer drug, AL-LAD was made illegal in Sweden on January 26, 2016.
Switzerland: 21 substances, including AL-LAD, were added to the list of illegal substances including on December 1, 2015. It is a controlled substance specifically named under Verzeichnis E.
Turkey: AL-LAD is illegal in Turkey as of February 2016.
United Kingdom: As of January 7, 2015, AL-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: AL-LAD is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
ETH-LAD
ALD-52
LSZ
LSD
AL-LAD (Wikipedia)
AL-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy AL-LAD Thread - Part 1 (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.

Detection Methods

Urine Detection

AL-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.

Blood and Serum Detection

Blood detection windows for AL-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.

Standard Drug Panel Inclusion

AL-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.

Confirmatory Methods

When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.

Reagent Testing (Harm Reduction)

For harm reduction identification, the Ehrlich reagent is the primary tool for AL-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens The toxicity and long-term health effects of recreational AL-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AL-LAD is a research chemical with very little history of human usage.

As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute AL-LAD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, AL-LAD is able to be considered non-addictive, with an extremely low toxicity relative to dose. It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute AL-LAD exposure.

It is strongly recommended that one uses harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, AL-LAD is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of AL-LAD is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). AL-LAD presents cross-tolerance with all psychedelics, meaning that after the use of AL-LAD all psychedelics will have a reduced effect.

Overdose

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of AL-LAD. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.

Addiction Potential

not habit-forming

Overdose Information

Overdose

Austria: AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Denmark: As of August 25, 2015, AL-LAD is specifically named on the list of illegal substances.
Germany: AL-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: AL-LAD is a controlled substance in Japan effective February 28th, 2020.
Latvia: AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Sweden: Following its sale as a designer drug, AL-LAD was made illegal in Sweden on January 26, 2016.
Switzerland: 21 substances, including AL-LAD, were added to the list of illegal substances including on December 1, 2015. It is a controlled substance specifically named under Verzeichnis E.
Turkey: AL-LAD is illegal in Turkey as of February 2016.
United Kingdom: As of January 7, 2015, AL-LAD is specifically named in the U.K. Misuse of Drugs

Legal Status

Austria: AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Denmark: As of August 25, 2015, AL-LAD is specifically named on the list of illegal substances.
Germany: AL-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: AL-LAD is a controlled substance in Japan effective February 28th, 2020.
Latvia: AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Sweden: Following its sale as a designer drug, AL-LAD was made illegal in Sweden on January 26, 2016.
Switzerland: 21 substances, including AL-LAD, were added to the list of illegal substances including on December 1, 2015. It is a controlled substance specifically named under Verzeichnis E.
Turkey: AL-LAD is illegal in Turkey as of February 2016.
United Kingdom: As of January 7, 2015, AL-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: AL-LAD is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
ETH-LAD
ALD-52
LSZ
LSD
AL-LAD (Wikipedia)
AL-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy AL-LAD Thread - Part 1 (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.

Cognitive(18)

Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...

Full	almost immediately after ingestion
Half	5-7 days
Zero	14 days

AL-LAD

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(13)

Tactile(1)

Cognitive & Perceptual Effects

Visual(15)

Pharmacology

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (6)

Tips (11)

Community Discussions (4)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(18)

Auditory(3)

Multi-sensory(1)

Transpersonal(4)